The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

ISA Pharmaceuticals B.V. presented the first clinical data of the combination of ISA101b and Regeneron’s anti-PD-1 Libtayo® at the ASCO annual meeting in Chicago.